<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">AER</journal-id><journal-title-group><journal-title>Advances in Enzyme Research</journal-title></journal-title-group><issn pub-type="epub">2328-4846</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/aer.2019.73003</article-id><article-id pub-id-type="publisher-id">AER-95404</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject><subject> Engineering</subject><subject> Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Primer-Like Inhibitors for DNA Repair Enzymes of the AML-HL60 and WERI-1A/Y79 Malignant Cells
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sergei</surname><given-names>V. Stovbun</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kirill</surname><given-names>V. Ermakov</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Alexander</surname><given-names>A. Bukhvostov</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Alexander</surname><given-names>S. Vedenkin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Dmitry</surname><given-names>A. Kuznetsov</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>N.N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow, Russia</addr-line></aff><aff id="aff2"><addr-line>Faculty of Biomedicine, N.I. Pirogov Russian National Research Medical University, Moscow, Russia</addr-line></aff><pub-date pub-type="epub"><day>27</day><month>09</month><year>2019</year></pub-date><volume>07</volume><issue>03</issue><fpage>27</fpage><lpage>44</lpage><history><date date-type="received"><day>6,</day>	<month>August</month>	<year>2019</year></date><date date-type="rev-recd"><day>24,</day>	<month>September</month>	<year>2019</year>	</date><date date-type="accepted"><day>27,</day>	<month>September</month>	<year>2019</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  A conventionally synthesized thio- and cyano-modified single-stranded 
  poly(dNTP) sequences of different molecular sizes (20
  &lt;i&gt;
  n
  &lt;/i&gt;
   
  -
   200
  &lt;i&gt;
  n
  &lt;/i&gt;
  ) and the same lengths routine poly(dNTP) and poly(NTP) species were obtained through the good services provided by the Russian Federal Bioorganic Products Group and by the ThermoFischer, Inc., and then tested for their impact on catalytic activities of 
  &lt;i&gt;
  β
  &lt;/i&gt;
  -like DNA polymerases from chromatin of HL-60, WERI-1A and Y-79 cells as well as for the affinity patterns in DNApol
  &lt;i&gt;
  β
  &lt;/i&gt;
  -poly(dNTP)/
   
  (NTP) pairs, respectively. An essential link between the lengths of ultrashort (50
  &lt;i&gt;
  n
  &lt;/i&gt;
   
  -
   100
  &lt;i&gt;
  n
  &lt;/i&gt;
  ) single-stranded poly(dNTP) sequences of different structures and their inhibitory effects towards the cancer-specific DNA polymerases 
  &lt;i&gt;
  β
  &lt;/i&gt;
   has been found. A possible significance of this phenomenon for both DNA repair suppression in tumors and a consequent anti-cancer activity of the DNA repair related short poly(dNTP) fragments has been for the first time emphasized with a respect to their pharmacophore revealing potential. Thus, this work presents an experimental attempt to upgrade a contemporary attitude towards the DNA derived products applied for anti-cancer agenda, particularly, for acute myeloid leukemia and retinoblastoma cell DNA repair machinery breakdown. In this study, tumor specific DNA polymerases 
  &lt;i&gt;
  β
  &lt;/i&gt;
   were 
  found of being the targets for attack promoted with the primer-like single-stranded DNA fragments followed by consequent cytostatic phenomena. A novel concept of the DNA related anti-cancer medicines is under discussion.
 
</p></abstract><kwd-group><kwd>Magnetic Isotope Effects (MIE)</kwd><kwd> DNA Repair</kwd><kwd> DNA Polymerases</kwd><kwd> DNA-Enzyme Binding</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>A background-lying platform of this work derives from experimental data on magnetic isotope effects (MIE) towards both DNApolβ catalytic activity [<xref ref-type="bibr" rid="scirp.95404-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref3">3</xref>] and the viability of cancer cells [<xref ref-type="bibr" rid="scirp.95404-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] . Thus, a sharp decrease of the survival ability patterns of <sup>25</sup>Mg<sup>2+</sup>-treated AML/HL-60 cells as compared to abundant spinless, non-magnetic, magnesium ions impact has been found [<xref ref-type="bibr" rid="scirp.95404-ref1">1</xref>] . Furthermore, a similar result was then obtained on the same leukemia cells treated with magnetic, nuclear spin possessing, <sup>43</sup>Ca<sup>2+</sup> and <sup>67</sup>Zn<sup>2+</sup> ions [<xref ref-type="bibr" rid="scirp.95404-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref3">3</xref>] as well as on human retinoblastoma cells subjected to these metal isotopes [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref3">3</xref>] .</p><p>It was also shown that a processivity of beta-like DNA polymerases isolated from the all above mentioned malignant cells depends on MIE, so the resulted DNA fragment sizes becomes shorter within a 40n - 250n range following the increase of magnetic isotope content in a total metal pool [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref3">3</xref>] . For instance, an up to 58% elevation of <sup>43</sup>Ca<sup>2+</sup> content leads to a monotonic decrease of sizes of polynucleotides processed from average 230n - 250n to an abnormal (DNA repair invalid) 36n - 40n as directed by beta-like DNA polymerases from Y-79 and WERI-1A retinoblastoma cells [<xref ref-type="bibr" rid="scirp.95404-ref1">1</xref>] .</p><p>This nuclear-magnetic control over the DNA synthesis, therefore, allows coming up with a firm statement that a replication mechanism involves some ion-radical steps consisting of the ion-radical pairs formation [<xref ref-type="bibr" rid="scirp.95404-ref1">1</xref>] . A key element of this mechanism deals with an electron transfer from the nascent DNA deoxyribose anion to a bivalent ion coordinated inside the DNA polymerase catalytic site [<xref ref-type="bibr" rid="scirp.95404-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref4">4</xref>] (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>However, from the chemical physics point of view, it is still obscure what makes the difference between molecular dynamics designs of these ion-radical DNA synthesis paths processed in healthy and malignant cells. Noteworthy, within the DNApolβ catalytic site nanotopology landscape which provides a</p><p>“compartment” for this reaction (10 - 15 nm or less), all physical parameters describing a molecular machinery in normal and cancer cells at proliferation rates observed are identical or pretty close to each other [<xref ref-type="bibr" rid="scirp.95404-ref5">5</xref>] - [<xref ref-type="bibr" rid="scirp.95404-ref10">10</xref>] .</p><p>Obviously, the DNA synthesis reaction [<xref ref-type="bibr" rid="scirp.95404-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref3">3</xref>] is unlikely a source for apoptosis of tumor cells as relates to dependence of their viability on MIE [<xref ref-type="bibr" rid="scirp.95404-ref1">1</xref>] . Nonetheless, this MIE-viability dependence might have a link to DNA repair activity expressed by beta-like DNA polymerases in neoplasma [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref11">11</xref>] .</p><p>According to our assumption, these enzymes are to produce the ultrashort PDRN sequences (≈40n) playing a role of DNApolβ inhibitors. Acting as the DNA repair limiting/damaging factors, these endogenous inhibitors may promote an essential anti-cancer effect. In case of <sup>25</sup>Mg/<sup>43</sup>Ca/<sup>67</sup>Zn-induced impacts on enzymatic activity in situ, these inhibitors might be originated as a direct response to MIE.</p><p>Moreover, due to a random mode of the cancer-specific repair-required local DNA damages, the DNA repair itself means a wide variability in primary structures of the repair-related PDRN species. This also means that the PDRN inhibitory function should be determined predominantly, if not exclusively, by the lengths of these sequences. These lengths alone might determine not only the molecular dynamics in DNApolβ-PDRN docking pairs but, simultaneously, they might make an impact on specific Coulomb and dispersion couplings and, hence, on the mean amounts of hydrogen bonds per one nucleotide of the DNA primer inside the enzyme catalytic site.</p><p>So if this assumotion is true, the DNApolβ activity must be “suppressible” by ≈ 40n-long polynucleotides regardless on their primary structures. This would make the MIE-promoting treatment a legitimate may to gain the in situ anti-cancer molecular events.</p><p>The aim of a present study is to test this hypothesis. For this purpose, several types of synthetic single-stranded polynucleotides (both DNA- and RNA-like ones) with molecular sizes ranged in 20n - 200n interval were investigated to reveal 1) their effects on catalytic activities of several beta-like DNA polymerases from HL-60, Y-79 and WERI-1A cancer cells, and 2) their enzyme-binding parameters. A selection of these peculiar cell models was determined solely by a sharp difference between the tumor proliferation rates, “aggressive” high (acute myeloid leukemia) and relatively low (retinoblastoma) [<xref ref-type="bibr" rid="scirp.95404-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref10">10</xref>] and, hence, by the difference in contributions made by the DNA repair key enzymes into the cancer cell survival capabilities.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Reagents and Disposal Materials</title><p>Aphidicolin (Fluka, Switzerland); ddTTP (Boehringer-Mannheim, Germany); Proteinase K (Serva, Germany); HSA (Sigma, USA); yeast tRNA (Serva, Germany); calf thymus DNA primer (Merk, Germany); dATP, dTTP, dCTP, dGTP (Serva, Germany); dioxane- and toluene-based media for liquid beta-scintillation count MS460 and MS710 (Merk, Germany); CS20 25 mm fiberglass filters (Millipore, France); AccuPrep DNA extraction K2600 kit (Bioneer, Rep. Korea); [Methyl-1,2-<sup>3</sup>H]dTTP, 120 - 160 Ci/mmol (Amersham, UK).</p></sec><sec id="s2_2"><title>2.2. Ligands</title><p>Poly(dT)<sub>25</sub>, Poly(dT)<sub>50</sub>, Poly(dT)<sub>100</sub>, Poly(dT)<sub>200</sub> (ThermoFisher, USA); Poly(A)<sub>49</sub>, Poly(2-thio-dC)<sub>49</sub>, Poly(dT)<sub>40</sub> (IBC RAS, Russia); Poly(dT)<sub>40</sub>, Poly(dT)<sub>80</sub> (ICBFM RAS, Russia); Poly([2-<sup>14</sup>C]CN-dT)<sub>40</sub>, 20 - 38 Ci/mmol; Poly([2-<sup>14</sup>C]CN-dT)<sub>80</sub>, 20 - 32 Ci/mmol; Poly([5-<sup>14</sup>C]CN-dT)<sub>40</sub>, 18 - 24 Ci/mmol; Poly([5-<sup>14</sup>C]CN-dT)<sub>80</sub>, 16 - 22 Ci/mmol (Perkin Elmer, USA).</p></sec><sec id="s2_3"><title>2.3. Enzymes</title><p>PAGE-homogenous beta-like monomeric, 66.5 kDa and 23.5 kDa, DNA polymerases (EC 2.7.7.7) purified from chromatine of HL-60 acute myeloid leukemia cells [<xref ref-type="bibr" rid="scirp.95404-ref11">11</xref>] and WERI-1A, Y-79 retinoblastoma cells [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] were employed. Thus, to purify these chromatine-associated DNA repair programming enzymes, the following [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref11">11</xref>] —promoted technique has been used. First, the chromatin fraction of the cell lysate was obtained. For this purpose, the protein containing crude nuclei phenol-chloroform extracts [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref11">11</xref>] were mixed with 10 volumes of an ice-cold acetone and kept at +4˚C overnight. An acetone-insoluble material was precipitated at 20,000 rpm, 20 min, +4˚C. The pellets were extensively re-washed with acetone using the same procedure and then dissolved in 5 - 6 volumes (w/v) of 25 mM potassium-phosphate (pH 6.30)/0.5% NaCl/1.5 mM EDTA/0.01% glutathione/0.05% heparin/1.0% 2-mercaptoethanol/80 - 100 U/mL nuclease S followed by 40 min incubation at +37˚C. All post-incubation mixtures were treated by sonication at 80 KHz, 30 min, +60˚C, under a non-stop extensive shaking. Then these mixtures were submitted to a scalar fractionation path reaching the 30% - 70% ammonium sulfate saturation, consequently. The precipitates obtained were collected at 10,000 rpm, 20 min, and dissolved in 15 mM potassium phosphate buffer (pH 6.0)/0.2% NaCl (10 vols, w/v). The solutions were subjected to dialysis against 20 mM potassium phosphate buffer (pH 6.0) and lyophilized.</p><p>The lyophilized powders were first dissolved in 15 mM potassium phosphate (pH 6.30)/5.0 mM MgCl<sub>2</sub>/1.5 mM EDTA/0.0001% sodium azide and passed through the fiberglass filters with 0.3 - 0.4 μ pore diameter (Millipore 5R, Millipore, France). The transparent solutions were subjected to ultrafiltration on membranes with the molecular size exclusion limit of 5.0 kDa at 800 p.s.i. (Diaflo Y5.0 25 mm membranes, Amicon BV, The Netherlands). The membrane-re- tained material was then extracted with 10 mM Tris-HCl (pH 8.0)/1.0% 2-mer- captoethanol (v/v), 5.0 mL per a razor-disintegrated membrane, +30˚C, 12 hrs, with a following concentration in a rotor evaporizer.</p><p>The 1.5 - 2.5 mL samples were then applied onto a 1.5 &#215; 50 cm (V = 98 mL) column packed with the TOYOPEARL HW 55F gel and equilibrated by the eluent buffer consisting of 15 mM potassium phosphate (pH 6.30)/5.0 mM MgCl<sub>2</sub>/ 0.0001% sodium azide. Elution rate: 0.8 mL/min (room temperature). In each one of the consequently eluted 1.5 mL fractions, the DNA polymerase activity has been measured according to [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref11">11</xref>] .</p></sec><sec id="s2_4"><title>2.4. Enzyme Activity Estimation</title><p>Beta-like catalytic activity values were expressed in amounts of [3H]dTTP incorporated into nascent DNA chains in 1 min of incubation at optimal conditions corrected per 1.0 mg of pure enzyme protein ([3H]DNAcpm/mg protein) as described in [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref11">11</xref>] . The enzyme catalytic activity was measured in 0.15 mL incubation mixtures consisting of 50 mM Tris-HCl (pH 8.0)/8.0mM dithiothreitol/15 mM MgCl<sub>2</sub>/15% glycerol (v/v)/27 2 μg act DNA, calf thymus/50 μg each of dATP, dCTP, dTTP, dGTP/0.25 μmole [Methyl-1,2-<sup>3</sup>H]dTTP (90 - 120 Ci/mmol, NET520A, NEN)/150 mM NaCl. The tritium-labeled nucleotide was purchased from New England Nuclear, USA. These compound concentration values were first pre-optimized within both pH 6.0 - 9.0 and 5.0 mM - 50.0 mM MgCl<sub>2</sub> ranges. These mixture samples were first pre-incubated at +37˚C for 60 min. Then 5.0 - 7.5 μg of pure enzyme was added to each one of these running samples and they were incubated at +37˚C for 60 min longer. The ice cold incubation samples (0˚C, 60˚C after pre-incubation) as well as the trypsin treated samples (20 μg/mL trypsin, Merck GmbH, Germany, +37˚C, 60˚C) were taken for controls.</p><p>The post-incubation mixtures were subjected to a quantitative extraction of the DNA ultramicro-amounts using an AccuPrep Genomic DNA Extraction Kit (Bioneer Corp., Korea).</p></sec><sec id="s2_5"><title>2.5. DNA and Protein Measurements</title><p>The DNA ultramirco amounts measurements were performed in diluted water solutions according to [<xref ref-type="bibr" rid="scirp.95404-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref13">13</xref>] . The protein ultramicro amounts were estimated by method [<xref ref-type="bibr" rid="scirp.95404-ref14">14</xref>] modified in [<xref ref-type="bibr" rid="scirp.95404-ref12">12</xref>] .</p></sec><sec id="s2_6"><title>2.6. Radioactivity Measurements</title><p>For [<sup>3</sup>H] and [<sup>14</sup>C] radioactivity quantitative detection, the cpm values were determined using the DNA-retaining fiberglass filters (DNApolβ post-incubation ethanol-precipitation pellets) [<xref ref-type="bibr" rid="scirp.95404-ref11">11</xref>] placed into dioxan or tolyene media [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref11">11</xref>] with a following processing in Wallac 2200LX liquid scintillation counter (Wallac, Finland).</p></sec><sec id="s2_7"><title>2.7. Ligand-Enzyme Binding Measurements</title><p>To quantify a ligand-enzyme binding patterns, a conventional criteria such as K<sub>dis</sub> (K<sub>d</sub>) and A<sub>c</sub> were taken into account.</p><p>A Baileyan model was applied for an algorithm leading to a ligand-enzyme (ligand-receptor) dissociation constant estimate [<xref ref-type="bibr" rid="scirp.95404-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref15">15</xref>] .</p><p>In this approach, a ligand-receptor interaction R + L ⇄ β α RL , where R is the receptor, L is the ligand, RL is the ligand-receptor complex, α is the probability of formation of a complex molecule, and β is the probability of its dissociation. If the random number of ligand-receptor complex molecules is x, and the initial number of receptors is R 0 , the number of free receptors makes R 0 − x . Assume that the process unfolds under the condition of large ligand surplus, so that the number of ligand molecules stays equal to its initial value L 0 . The formation of ligand-receptor complexes is described by the function f 1 = α L 0 ( R 0 − x ) , and their decomposition—by f − 1 = β x . Bailey’s equation system is:</p><p>∂ M ( θ , t ) ∂ t = L 0 R 0 α ( e θ − 1 ) M ( θ , t ) − L 0 α ( e θ − 1 ) ∂ M ( θ , t ) ∂ θ     + β ( e − θ − 1 ) ∂ M ( θ , t ) ∂ θ</p><p>d k 1 ( t ) d t = L 0 R 0 α − L 0 α k 1 ( t ) − β k 1 ( t ) ,</p><p>d k 2 ( t ) d t = L 0 R 0 α − L 0 α k 1 ( t ) − 2 L 0 α k 2 ( t ) − β k 1 ( t ) + 2 β k 2 ( t ) ,</p><p>k 1 ( t ) = m ( t ) = β l r β l + α ( 1 − exp [ − ( β l + α ) t ] ) ,</p><p>k 2 ( t ) = σ 2 ( t ) = α β l r ( β l + α ) 2 ( 1 − exp [ − ( β l + α ) t ] )                                           + β 2 l 2 r ( β l + α ) 2 exp [ − ( β l + α ) t ] ( 1 − exp [ − ( β l + α ) t ] ] )</p><p>Following this algorithm, an experimental data on the ligand-enzyme complexes stability in water solutions obtained by techniques described in [<xref ref-type="bibr" rid="scirp.95404-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref15">15</xref>] and modified in [<xref ref-type="bibr" rid="scirp.95404-ref16">16</xref>] , and affected by temperature/ultrasound/ionic strength were processed using a LQ170 SigmaLab software in HP9000 analytical system (Hewlett Packard, USA).</p><p>For a non-specific binding control, HSA and denaturated-renaturated misfolded yeast tRNA were employed as the pseudoligands [<xref ref-type="bibr" rid="scirp.95404-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref18">18</xref>] .</p><p>In all enzyme-ligand coupling tests, the enzyme required optimal catalytic parameters [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref11">11</xref>] were held for 40 min, +37˚C, while the following ligand concentrations kept at 0.1 μM, 0.5 μM, 10.0 μM, 20.0 μM, 50.0 μM, as recommended in [<xref ref-type="bibr" rid="scirp.95404-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref17">17</xref>] .</p><p>The UV-spectrophotometry (Lambda 1050 Scanning Spectrophotometer, Perkin Elmer, USA) was employed using the Spectra Manager II cross-platform software (JASCO, USA) for automated data treatment with an aim to gain the A<sub>c</sub> index indicating an extent of polynucleotide release from ligand-enzyme in water solution owing to a certain consent of A<sub>210</sub>, A<sub>254</sub>, A<sub>280</sub> values, A c = [ A 254 / ( A 280 − A 254 ) ] / A 210 [<xref ref-type="bibr" rid="scirp.95404-ref16">16</xref>] .</p></sec><sec id="s2_8"><title>2.8. Statistics</title><p>A Dunnett’s non-parametric (n ≤ 6) technique was used to elucidate reproductability of the data along with a significance of differences in control-experiment comparisons [<xref ref-type="bibr" rid="scirp.95404-ref19">19</xref>] .</p></sec></sec><sec id="s3"><title>3. Results</title><p>A variable set of polynucleotide ligands (see Methods) was tested for both inhibitory effects and the ligand-enzyme binding properties using beta-like DNA polymerase species from acute myeloid leukemia (HL-60) and retinoblastoma (WERI-1A, Y-79) cells.</p><p>As seen from the data presented in <xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig3">Figure 3</xref>, no matter what ligand concentration tested and whatever enzyme sample coupled, a molecular size of synthetic polynucleotide is the only, crucial, impact-making factor. It should be emphasized that a maximal inhibition effects were observed in cases of 50n - 100n-long polynucleotides (<xref ref-type="fig" rid="fig2">Figure 2</xref>(C) and <xref ref-type="fig" rid="fig2">Figure 2</xref>(D)), Figures 3(A)-(E)), while a post-denaturation misfolded tRNA test show no inhibition</p><p>effect at all (<xref ref-type="fig" rid="fig3">Figure 3</xref>(A) and <xref ref-type="fig" rid="fig3">Figure 3</xref>(B)). As per Aphidicolin and ddTTP controls,they just prove a true beta-specific nature of enzymes tested [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref11">11</xref>] (<xref ref-type="fig" rid="fig2">Figure 2</xref>(A)).</p><p>Unlike polydeoxyribonucleotides (PDRN), polyribonucleotides were found to be inert towards the DNApolβ processivity regardless on lengths of these ligand molecules (<xref ref-type="fig" rid="fig3">Figure 3</xref>(A) and <xref ref-type="fig" rid="fig3">Figure 3</xref>(B)).</p><p>The affinity isotherms clearly show an essential difference between the ligand-enzyme complex stability patterns, K<sub>d</sub> and A<sub>c</sub> (see Methods), estimated for numerous compositions of these couples (<xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="fig" rid="fig5">Figure 5</xref>). Thus, dissociation constant K<sub>d</sub> for Poly(dT)<sub>50</sub>-DNApolβ was found by 2.5-fold smaller as compared to Poly(dT)<sub>200</sub>-DNApolβ pair (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p><p>In all cases studied, except for the RNA-like Poly(A)<sub>49</sub>-containing pairs (<xref ref-type="fig" rid="fig5">Figure 5</xref>), K<sub>d</sub> and A<sub>c</sub> values are minimal when the ligand length is close to 50n (<xref ref-type="fig" rid="fig6">Figure 6</xref>). For all RNA-like ligands, the high values of K<sub>d</sub> and A<sub>c</sub> were found practically equal to the ones estimated for Poly(dT)<sub>200</sub> (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p><p>The data presented in <xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig3">Figure 3</xref> leaves no doubt about a maximal inhibitory efficiency provided by ultrashort, 40n - 50n in length, cyano-polydeoxyribothymidyl derivatives. These agents are to show as high as nearly 6.5-fold extent of enzyme suppression. That does not mean, however, that</p><p>this particular type of “pseudoprimers” is the only one capable to play a role of a powerful DNApolβ inhibitor. A truly crucial parameter to reveal a potential pharmacophore signs have nothing to do with a structure of DNA fragments being entirely related to its molecular size (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><p>So the results observed looks worthy of not indicating to any particular and perfect pharmacophore found but, instead, of a detailed analysis as a new platform to upgrade a whole approach towards the DNA derivatives in a current</p><p>anti-cancer agenda. This a Discussion of our work is all about.</p></sec><sec id="s4"><title>4. Discussion</title><p>A wide diversity of investigated synthetic homopolynucleotides and their monotonic thio- and cyano-derivatives is itself a prove for universal, indiscriminate, mode of DNApolβ inhibition effect we described. This is in a favor with our assumption stated that the key role in this phenomenon belongs exclusively to molecular sizes of small DNA fragments regardless on their primary structure peculiarities.</p><p>The ligands diversity mentioned makes no way to explain a formation of the ligand-enzyme complexes just by a routine docking (“complimentary”) paradigm. This DNA-protein binding act may involve some random appearing hydrogen bonds, Coulomb hyperfine coupling along with dispersion interaction and, last not least, the hydrophobic connections, might also be a case in this scenario. A key point of this model derives from the homopolynucleotides related data and reveals that the mean energy of these “weak” interaction depends on the length of a ligand but not of its structure.</p><p>A similar event occurs in the DNA repair process as long as a randomly appeared local DNA damage comes first. In this case, a clearly indiscriminate mode of the ligand-enzyme coupling is a consequence of unpredictable variability in primary structures of DNA fragments suitable for the repair purposes.</p><p>Therefore, a polynucleotide length alone is an impact-making factor towards the DNApolβ catalytic function. This factor might determine a formation of the above listed “weak” non-covalent interactions and, hence, to control the mean amount of hydrogen bonds per one nucleotide of DNA-primer (ligand) inside the DNA polymerase catalytic site. That is indeed critical for the enzyme suppression in situ.</p><p>All the affinity isotherms presented and a variable ligand-enzyme binding data (Figures 4-6) reveals a maximal strength of this peculiar intermolecular interaction within the short interval of ligand sizes, 50n - 100n. This is to confirm that the enzyme inhibition we observed (Figures 2(B)-(E), <xref ref-type="fig" rid="fig3">Figure 3</xref>) is indeed a consequence of the stable ligand-enzyme pair formation which has nothing to do with either the solution properties changes or the enzyme surrounding disperse phase modulations.</p><p>A comparison between the ligand amounts bound with (a) DNApolβ and (b) HSA show that the ligand-enzyme complex includes two molecules of ligand per one molecule of enzyme, while the ligand-HSA (control) pair contains just one ligand per HSA molecule (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig7">Figure 7</xref>, <xref ref-type="fig" rid="fig8">Figure 8</xref>). This is in a favor to a mere fact of existance of two separate Mg<sup>2+</sup>-coordinating catalytic sites in β- and β-like DNA polymerases [<xref ref-type="bibr" rid="scirp.95404-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref22">22</xref>] .</p><p>Let’s evaluate the activation energy value for a ligand-enzyme complex dissociation following the data listed in <xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="fig" rid="fig8">Figure 8</xref>. Obviously, a</p><p>dependence of K<sub>d</sub> on temperature has a clear Ahrrenius mode:</p><p>K d = K 0 exp ( − E / R T ) (1)</p><p>where R—a universal gas constant and T-enzyme functioning temperature.</p><p>Taking into account a low level of the temperature interval tested as compared to an initial T<sub>0</sub> = 298K, we’ll use further a linear decay as T in (1). To estimate E, a linear reguliarity must be treated as:</p><p>ln K d ≅ ln K 0 − E / ( R T 0 ) + E Δ T / R T 0 2 (2)</p><p>where Δ T is a temperature change in experiment (<xref ref-type="fig" rid="fig7">Figure 7</xref> and <xref ref-type="fig" rid="fig8">Figure 8</xref>).</p><p>The Equation (2) revealed activation energy value E was found 15 kJ for Poly(dT)<sub>200</sub> ligand within a whole range of temperatures tested, while the very same dependence for Poly(dT)<sub>50</sub> include two linear branches crossing each other nearby the 40˚C point where, most likely, a slight protein denaturation starts (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Once the temperature is close to an enzyme function required optimal level (25˚C - 35˚C), the Equation (2) revealed E<sub>50</sub> = 70 kJ/mole whereas this value estimated at 40˚C is as low as 15 kJ/mole (<xref ref-type="fig" rid="fig7">Figure 7</xref>). The attention catching point here is that the E value measured at the enzyme denaturation launch-point (40˚C) is exactly the same as it has been found in case of the “inert”, non-inhibiting, polydeoxyribonucleotide ligands. This supports a statement on the enzyme inactivating protein structure dynamics initiated starting with a 40˚C heating point. A lack of two-compartment, “angle-breaking”, K d = f ( T ) dependence for long ligands and their E values low level are in a good accordance with a high probability of 3D-compactization of such sequences at our test conditions [<xref ref-type="bibr" rid="scirp.95404-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref23">23</xref>] .</p><p>It’s easy to find out that the inhibition-promoting Poly(dNTP) species provide a pretty low value of activation energy for dissociation with DNApolβ-HL60, ε = 1.40 kJ/mole. That means, the complimentary hydrogen bonds do not contribute to formation of these particular Poly(dNTP)-enzyme complexes which is a prove for the absence of the affinity-specific, true docking links in these pairs. Most probably, this remarkable 1.40 kJ/mole value is determined by the U<sub>d</sub>-dispersion related weak Van der Waals interactions along with a U<sub>q</sub> Coulomb hyperfine coupling. These kinds of the ligand-enzyme complex stabilizing links are rather superficial ones due to both a U d ~ 1 / r 6 potential and the efficient screen-like separation of Coulomb forces in water occurred within a distance smaller than 0.4 nm [<xref ref-type="bibr" rid="scirp.95404-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref24">24</xref>] . This certainly takes into account the superficial hydrophobic bounds as well which are nothing but the result of a cooperative (cumulative) act of all the above specified forces [<xref ref-type="bibr" rid="scirp.95404-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref24">24</xref>] .</p><p>So the key role in formation of Poly(dNTP)/DNApolβ complexes belongs to Van der Waals bounds which energy corresponds directly to either 1) the efficient surface of ligand-enzyme pair or 2) a length of an enzyme-bound ligand.</p><p>Furthermore, since the mean value of the U<sub>d</sub> dispersion patterns is hardly dependent on the element composition, and as long as the amounts of charged groups in U<sub>q</sub>-determining Poly(dNTP) ligands tested are about the same, a very similar parameters of their inhibitory activity should be expected then. This explains well a lack of dependence of inhibitory capabilities of these ligands on their nucleotide composition (Figures 2(B)-(E), <xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><p>Once ε ~ R T , we might suppose that the short ligands (50n - 100n, or shorter) are to get bound with the enzyme molecule throughout a whole linear chain, i.e. through nearly every nucleotide of Poly(dNTP) sequence.</p><p>Using the Ahrrenius equation, we may evaluate a ratio between the ligand- enzyme binding time values τ for Poly(dNTP)<sub>20</sub> and Poly(dNTP)<sub>50</sub>, respectively:</p><p>τ 20 / τ 50 = exp ( − Δ n ε / R T ) ≅ 10 − 7 (3)</p><p>where Δ = 30 (difference in lengths between 50n and 20n). It shows that a short time of binding τ 20 does not allow n<sub>20</sub>-ligand to promote a sharp suppression of the enzyme activity. A shorter time for the ligand “neighboring” around the enzyme catalytic site, the lesser inhibitory effect to be expressed.</p><p>On other hand, the longest ligands tested were found to be a rather poor inhibitors as well (<xref ref-type="fig" rid="fig2">Figure 2</xref>(E), <xref ref-type="fig" rid="fig4">Figure 4</xref>) due to their compactization-caused small square of the enzyme-ligand efficient interaction [<xref ref-type="bibr" rid="scirp.95404-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref25">25</xref>] as also seen from Equation (3).</p><p>As per a zero inhibition affect shown by RNA-like ligands tested (<xref ref-type="fig" rid="fig3">Figure 3</xref>(A) and <xref ref-type="fig" rid="fig3">Figure 3</xref>(B)), their remarkable refolding capabilities [<xref ref-type="bibr" rid="scirp.95404-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref25">25</xref>] and [– O-----Mg<sup>2+</sup>] coordination input [<xref ref-type="bibr" rid="scirp.95404-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref27">27</xref>] are presumably beyond this phenomenon.</p><p>A clear pharmacological potential of oligo- and polydeoxyribinucleotides is a subject for numerous experimental and clinical studies performed since early 1990s [<xref ref-type="bibr" rid="scirp.95404-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref29">29</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref30">30</xref>] . Their applied medicinal significance, however, were treated predominantly by focusing on the aptomer properties, i.e. on capabilities to find the specific target molecules such as signaling proteins, membrane receptors, chromatin structure elements, etc [<xref ref-type="bibr" rid="scirp.95404-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref31">31</xref>] . Unlike our present work, therefore, these studies are all about the true docking participants. The inhibitory power of Poly(dNTP) species we found has nothing to do with their structures and composition being entirely dependent on molecular size (Figures 2(B)-(E), <xref ref-type="fig" rid="fig3">Figure 3</xref>(A), <xref ref-type="fig" rid="fig3">Figure 3</xref>(C), <xref ref-type="fig" rid="fig3">Figure 3</xref>(D), <xref ref-type="fig" rid="fig3">Figure 3</xref>(E)). This allows to “turn the page” in a long record of polynucleotide medicinal applications by just paying attention to the Poly(dNTP) motion on how to shut down a DNA repair in malignant cells. It makes sense for DNApolβ, key DNA repair enzymes, are found hyperexpressed in response to a high frequency of DNA damages followed by an increase of the cancer related cell proliferation rate [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref20">20</xref>] . With a respect to this statement, it has been already emphasized that the members of this enzyme family are the “legitimate targets” for cytostatic inhibitors like dNTP antimetabolites [<xref ref-type="bibr" rid="scirp.95404-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref32">32</xref>] and magnetic metal isotopes [<xref ref-type="bibr" rid="scirp.95404-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref24">24</xref>] .</p><p>There is a good enough understanding on molecular mechanisms beyond the inhibition of the cancer-hyperexpressed DNApolβ species provided by magnetic isotopes of bivalent metals—<sup>25</sup>Mg, <sup>43</sup>Ca and <sup>67</sup>Zn [<xref ref-type="bibr" rid="scirp.95404-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref24">24</xref>] . In particular, these mechanisms are dealing with the origin of “too short”, DNA repair insufficient, DNA fragments [<xref ref-type="bibr" rid="scirp.95404-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref3">3</xref>] . This effect leads to a massive release of the DNA repair related 40n - 100n DNA sequences with the unpredictable, unique structures [<xref ref-type="bibr" rid="scirp.95404-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] , i.e. this provokes a magnetic isotope induced formation of the DNApolβ endogenous inhibitors. It looks like a good explanation for cytostatic activity shown by magnetic metal isotopes in several cancer cells [<xref ref-type="bibr" rid="scirp.95404-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref24">24</xref>] .</p><p>Everything we know about pharmacokinetics of various DNA-based drugs and pharmacophores indicates to the fact that their bioavailability is far of being perfect mostly because of inevitable nucleases attack [<xref ref-type="bibr" rid="scirp.95404-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref29">29</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref30">30</xref>] . So this is the hardest task to manage a targeted delivery of Poly(dNTP) sequences to the DNApolβ-operating in situ compartments, for which some certain nanocarriers required [<xref ref-type="bibr" rid="scirp.95404-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref33">33</xref>] . As for the magnetic metal ions, they can be delivered to the DNApolβ in situ targets with [<xref ref-type="bibr" rid="scirp.95404-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref24">24</xref>] or even without [<xref ref-type="bibr" rid="scirp.95404-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref3">3</xref>] nanocationite administration which would make the magnetic isotope effect a promising tool to gain the DNA repair machinery breakdown in neoplasma.</p><p>Knowing that the abundance of <sup>25</sup>Mg is relatively high (≈10%) and considering a remarkable role of magnesium in enzymatic phosphorylation processes [<xref ref-type="bibr" rid="scirp.95404-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref34">34</xref>] , it would be logical to suppose the existence of so called “hidden” effects of Magnesium-25 on numerous metabolic pathways. In this case, a high content of endogenous Fe<sup>2+</sup> in cells and tissues of a living organism becomes a natural limiting factor to prohibit any expression of magnetic isotope effects in vivo. This is in accordance with the data on correlations between the <sup>25</sup>Mg<sup>2+</sup>-affected ATP synthesis levels in mitochondria and the Fe<sup>2+</sup> contents in these mitochondria isolated from different rat tissues [<xref ref-type="bibr" rid="scirp.95404-ref34">34</xref>] as well as with the results stated an increase of Fe/Mg ratios in several types of cancer (ovarian cancer, renal adenocarcinoma, fibroblast lung cancer, hepatocellular cancer, osteosarcoma, thyroid follicular adenocarcinoma) compared to corresponding normal, non-malignant, tissues [<xref ref-type="bibr" rid="scirp.95404-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref32">32</xref>] .</p><p>A variety of clinical case reports showing an appearance of short (100n - 300n) single-stranded DNA fragmets in a blood plasma of oncology patients [<xref ref-type="bibr" rid="scirp.95404-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.95404-ref35">35</xref>] may now also be treated under a point of view of the probable DNA repair related origin of these tumor-released Poly(dNTP) sequences.</p><p>Last not least, the infamous quorum sensing phenomena [<xref ref-type="bibr" rid="scirp.95404-ref36">36</xref>] could be engaged with an effort to uncover a biological meaning of what we’ve found testing the capabilities of different Poly(dNTP) species to affect some tumor-specific DNA repair key enzymes.</p></sec><sec id="s5"><title>5. Conclusions</title><p>Ultrashort (40n - 100n) polydeoxyribonucleotides are found to be the efficient non-specific inhibitors of DNA polymerases β from chromatin of several cancer cells: HL-60, WERI-1A, Y-79.</p><p>Manifesting a positive correlation between these inhibitory capabilities and the strength of affinity in enzyme-ligand pairs, such poly(dNTP) species promote a sharp suppression of enzymatic catalysis regardless on their primary structures. Only molecular size matters.</p><p>The data presented show a clear regulatory potential of some short ssDNA entities once they are about to interact with the key DNA repair enzymes.</p><p>This may provide a promising platform for further research aiming to shut down the DNA repair machinery in malignancies.</p></sec><sec id="s6"><title>Acknowledgements</title><p>This work was performed within the aims and scope of the Russian Federal Specialized Program on priorities in science and technologies trends for 2014-2020 supported by Russian Federal Ministry of Science and University Education. The RF Government budget beyond.</p></sec><sec id="s7"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s8"><title>Cite this paper</title><p>Stovbun, S.V., Ermakov, K.V., Bukhvostov, A.A., Vedenkin, A.S. and Kuznetsov, D.A. (2019) Primer-Like Inhibitors for DNA Repair Enzymes of the AML-HL60 and WERI-1A/ Y79 Malignant Cells. Advances in Enzyme Research, 7, 27-44. https://doi.org/10.4236/aer.2019.73003</p></sec><sec id="s9"><title>Abbreviations</title><p>ssDNA, Single-Stranded DNA;</p><p>DNApolβ, DNA Polymerase Beta;</p><p>MIE, Magnetic Isotope Effects;</p><p>AML, Acute Myeloid Leukemia.</p></sec></body><back><ref-list><title>References</title><ref id="scirp.95404-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Buchachenko, A.L., Bukhvostov, A.A., Ermakov, K.V. and Kuznetsov, D.A. (2019) Nuclear Spin Selectivity in Enzymatic Catalysis. A Caution for Applied Biophysics. Archives of Biochemistry and Biophysics, 667, 30-35. https://doi.org/10.1016/j.abb.2019.04.005</mixed-citation></ref><ref id="scirp.95404-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Bukhvostov, A.A., Dvornikov, A.S., Ermakov, K.V., Kurapov, P.B. and Kyznetsov, D.A. (2017) Retinoblastoma: Magnetic Isotope Effects Might Make a Difference in the Current Anti-Cancer Research Strategy. Acta Medica (Hradec Kralove), 60, 93-96. https://doi.org/10.14712/18059694.2017.101</mixed-citation></ref><ref id="scirp.95404-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bukhvostov, A.A., Dvornikov, A.S., Ermakov, K.V. and Kuznetsov, D.A. (2017) Retinoblastoma Case: Shall We Get a Paramagnetic Trend in Chemotherapy? Archives of Cancer Research, 5, 158-162. https://doi.org/10.21767/2254-6081.100158</mixed-citation></ref><ref id="scirp.95404-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Chen, S.J. (2019) Site-Specific Binding of Non-Site-Specific Ions. Biophysical Journal, 116, 38-46. https://doi.org/10.1016/j.bpj.2019.04.038</mixed-citation></ref><ref id="scirp.95404-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Muller, W.E., Obermeyer, J. and Totsuka, A. (1974) Influence of Template Inactivators on the Binding of DNA Polymerases to DNA. Nucleic Acids Research, 1, 63-69. https://doi.org/10.1093/nar/1.1.63</mixed-citation></ref><ref id="scirp.95404-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Corces, M.R., Granja, J.M., Shams, S., Louie, B.H., Seoane, J.A., Zhou, W., Silva, T.C. and Chang, H.V. (2018) The Chromatin Accessibility Landscape of Primary Human Cancers. Science, 362, 16-28. https://doi.org/10.1126/science.aav1898</mixed-citation></ref><ref id="scirp.95404-ref7"><label>7</label><mixed-citation publication-type="book" xlink:type="simple">Ashley, J.S., Kronenberg, G.H., Lipman, K.R. and Bielka, H. (2019) Coupling the DNA Turnover Enzymes. Poly(dNMP) Ligands. In: Pitot, H. and Van Nijemen, J.T. Eds., Methods in Macromolecular Docking Research, University of Ghent Press, Ghent-Antwerp, 216-229.</mixed-citation></ref><ref id="scirp.95404-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Turgeon, M.O., Perry, N.J.S. and Poulogiannis, G. (2018) DNA Damage, Repair and Cancer Metabolism. Frontiers in Oncology, 8, 15-22. https://doi.org/10.3389/fonc.2018.00015</mixed-citation></ref><ref id="scirp.95404-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Breitenbach, M. and Hoffmann, J. (2018) Cancer Models. Frontiers in Oncology, 8, 401-419. https://doi.org/10.3389/fonc.2018.00401</mixed-citation></ref><ref id="scirp.95404-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Jain, R., Aggarwal, A.K. and Rechkoblit, O. (2018) Eukaryotic DNA Polymerases. Current Opinion in Structural Biology, 53, 77-87. https://doi.org/10.1016/j.sbi.2018.06.003</mixed-citation></ref><ref id="scirp.95404-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Bukhvostov, A.A., Shatalov, O.A., Orlov, A.P. and Kuznetsov, D.A. (2013) An Atypical DNA Polymerase Beta Overexpressed in Human AML/HL-60 Malignant Cells. Journal of Cancer Science and Therapy, 5, 94-99. https://doi.org/10.4172/1948-5956.1000191</mixed-citation></ref><ref id="scirp.95404-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Katoh, R. (2011) Analytical Techniques in Biochemistry and Molecular Biology. Springer Publ. GmbH, Berlin-Heidelberg.</mixed-citation></ref><ref id="scirp.95404-ref13"><label>13</label><mixed-citation publication-type="book" xlink:type="simple">Dewar, J.M. and Lyndall, D. (2012) Simple Non-Radioactive Measurement of Single-Stranded DNA. In: Bjergbaek, L., Ed., Methods in Molecular Biology, DNA Repair Protocols, Humana Press, Inc., Totowa, 920, 341-349. https://doi.org/10.1007/978-1-61779-998-3_24</mixed-citation></ref><ref id="scirp.95404-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Fukami, T., Uchiyama, K. and Yoshimura, Y. (1996) Ultramicroanalysis by Use of Light-Scanning Photoacoustic Densitometry of Electrophoresed Protein. Analytical Biochemistry, 238, 60-67. https://doi.org/10.1006/abio.1996.0251</mixed-citation></ref><ref id="scirp.95404-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Rastogi, C., Rube, H.T., Kribelbauer, J.F., Crocker, J., Locker, R.E., Martini, G.D. and Laptenko, O. (2018) Accurate and Sensitive Quantification of Protein-DNA Binding Affinity. PNAS, 115, E3692-E3701. https://doi.org/10.1073/pnas.1714376115</mixed-citation></ref><ref id="scirp.95404-ref16"><label>16</label><mixed-citation publication-type="book" xlink:type="simple">Laurent, C., Neurath, K.J., Baglioni, G. and Sieliwanowicz, B. (2019) Advances in Multiwave UV-Spectrophotometry: RNP/DNP Integrity Studies. In: Lindsey, A.L. and Cohen, K., Eds., Physics of Biopolymers, Adler &amp; Adler Publ., Perth, 41-56.</mixed-citation></ref><ref id="scirp.95404-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Chowdhury, N. and Bagchi, A. (2015) An Overview of DNA-Protein Interactions. Current Chemical Biology, 9, 71-83. https://doi.org/10.2174/2212796809666151022202255</mixed-citation></ref><ref id="scirp.95404-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Telashima, Y. (2019) Revival of Oligonucleotide Therapy Development. KOKEN Publ., Tokyo-Nagoya.</mixed-citation></ref><ref id="scirp.95404-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Byron, W.M., Hollander, B. and Hollander, M. (2007) Statistics. A Biomedical Introduction. Wiley-Blackwell Publ., Oxford-Weinheim.</mixed-citation></ref><ref id="scirp.95404-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Lavrik, I.N. (2014) Systems Biology of Death Receptor Networks: Live and Let Die. Cell Death &amp; Disease, 5, e1259-e1266. https://doi.org/10.1038/cddis.2014.160</mixed-citation></ref><ref id="scirp.95404-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Peterson, L.E. (2019) Small Molecule Docking of DNA Repair Proteins Associated with Cancer Survival Following PCNA Metagene Adjustment. A Potential Novel Class of Repair Inhibitors. Molecules, 24, 645-667. https://doi.org/10.3390/molecules24030645</mixed-citation></ref><ref id="scirp.95404-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Wu, Y., Lu, J. and Kang, T. (2016) Human Single-Stranded DNA Binding Proteins: Guardians of Genome Stability. Acta Biochimica et Biophysica Sinica, 48, 671-677. https://doi.org/10.1093/abbs/gmw044</mixed-citation></ref><ref id="scirp.95404-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Finkelsten, A.V. and Ptitsyn, O.V. (2012) Physics of Proteins. Nova Publ., Princeton.</mixed-citation></ref><ref id="scirp.95404-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Buchachenko, A.L. (2015) Magneto-Biology and Medicine. Nova Science Publ., New York.</mixed-citation></ref><ref id="scirp.95404-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Morten, M.J., Gamsjaejer, R., Cubeddu, L., Kariawasam, R., Peregrina, J., Penedo, J.C. and White, M.F. (2017) High Affinity RNA Binding by a Hyperthermophilic Single-Stranded DNA-Binding Protein. Extremophiles, 21, 369-379. https://doi.org/10.1007/s00792-016-0910-2</mixed-citation></ref><ref id="scirp.95404-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Lyu, J., Wang, S., Balius, T.E., Singh, I., Levit, A., Moroz, Y.S. and O’Meara, M.J. (2019) Ultra-Large Library Docking for Discovering New Chemotypes. Nature, 566, 224-229. https://doi.org/10.1038/s41586-019-0917-9</mixed-citation></ref><ref id="scirp.95404-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Ueda, S., Watanabe, I. and Taichi, K. (2019) Nucleic Acid-Based Drugs. Sumitomo Chemical Co. Ltd., Utajima-Osaka.</mixed-citation></ref><ref id="scirp.95404-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Udvardi, L. and Lakatos, S. (2019) Aptamers. Towards the Pharmacological Breakthrough. Alba Regia, Szegen-Budapest.</mixed-citation></ref><ref id="scirp.95404-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Zavyalova, E., Samoylenkova, N., Revishchin, A., Turashev, A., Gordeychuk, I., Golovin, A., Kopylov, A. and Pavlova, G. (2017) The Evaluation of Pharmacodynamics and Pharmacokinetics of Anti-Thrombin DNA Aptamer RA-36. Frontiers in Pharmacology, 8, 922-930. https://doi.org/10.3389/fphar.2017.00922</mixed-citation></ref><ref id="scirp.95404-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Squadrito, F., Bitto, A., Irrera, N., Pizzino, G., Pallio, G., Minutoli, L. and Altavilla, D. (2017) Pharmacological Activity and Clinical Use of PDRN (Polydeoxyribonucleotides). Frontiers in Pharmacology, 8, 224-233. https://doi.org/10.3389/fphar.2017.00224</mixed-citation></ref><ref id="scirp.95404-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Ashton, N.W., Bolderson, E., Cubeddu, L., O’Byrne, K.J. and Richard, D.J. (2013) Human Single-Stranded DNA Binding Proteins Are Essential for Maintaining Genomic Stability. BMC Molecular Biology, 14, 1-20. https://doi.org/10.1186/1471-2199-14-9</mixed-citation></ref><ref id="scirp.95404-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Bozic, I. and Nowak, M.A. (2017) Resisting Resistance. Annual Review of Cancer Biology, 1, 203-221. https://doi.org/10.1146/annurev-cancerbio-042716-094839</mixed-citation></ref><ref id="scirp.95404-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Ansari, A.S., Santerre, P.J. and Uludag, H. (2017) Biomaterials for Polynucleotide Delivery to Anchorage-Independent Cells. Journal of Materials Chemistry B, 5, 7238-7261. https://doi.org/10.1039/C7TB01833A</mixed-citation></ref><ref id="scirp.95404-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Svistunov, A.A., Napolov, Y.K., Bukhvostov, A.A., Shatalov, O.A., Alayutdin, R.N. and Kuznetsov, D.A. (2013) The Mitochondria Free Iron Content to Limit an Isotope Effect of 25Mg2+ in ATP Synthesis: A Caution. Cell Biochemistry and Biophysics, 66, 417-419. https://doi.org/10.1007/s12013-012-9486-3</mixed-citation></ref><ref id="scirp.95404-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Mouliere, F., Chandrananda, D., Piskorz, A.M., Moore, E.K., Morris, J., Ahlborn, L.B. and Rosenfeld, N. (2018) Enhanced Detection of Circulating Tumor DNA by Fragment Size Analysis. Science Translational Medicine, 10, 117-129.</mixed-citation></ref><ref id="scirp.95404-ref36"><label>36</label><mixed-citation publication-type="book" xlink:type="simple">Catachura, S.C., Leys, N. and Mastroleo, J. (2018) Quorum Sensing in Life Support Systems. In: Kalia, V.C., Ed., Quorum Sensing, Springer Nature, Ltd., Singapore, 249-260. https://doi.org/10.1007/978-981-13-0848-2_16</mixed-citation></ref></ref-list></back></article>